Lente insulin: Difference between revisions

From WikiMD's Wellness Encyclopedia

CSV import
 
CSV import
Tags: mobile edit mobile web edit
 
Line 1: Line 1:
'''Lente insulin''' is a type of [[insulin]] that was used in the management of [[diabetes mellitus]]. It is a mixture of 30% [[semilente insulin]] and 70% [[ultralente insulin]], which gives it an intermediate duration of action. Lente insulin was discontinued in the United States in 2005.
== Lente Insulin ==


==History==
[[File:Human-insulin-hexamer-3D-ribbons.png|thumb|right|3D structure of human insulin hexamer]]
Lente insulin was first introduced in the 1950s. It was developed as a longer-acting form of insulin to help people with diabetes maintain stable blood sugar levels throughout the day. Lente insulin was a popular choice for many years due to its intermediate duration of action and relatively low cost.


==Composition==
'''Lente insulin''' is a type of intermediate-acting [[insulin]] used in the management of [[diabetes mellitus]]. It is designed to mimic the body's natural pattern of insulin release and is typically administered to help control blood glucose levels throughout the day.
Lente insulin is a mixture of two types of insulin: semilente and ultralente. Semilente insulin is a short-acting insulin, while ultralente is a long-acting insulin. The combination of these two types of insulin gives lente insulin its intermediate duration of action.


==Use in Diabetes Management==
== History ==
Lente insulin was used in the management of both [[Type 1 diabetes|type 1]] and [[Type 2 diabetes|type 2 diabetes]]. It was typically administered once or twice daily to help control blood sugar levels. Lente insulin was often used in combination with other types of insulin or oral diabetes medications.
Lente insulin was developed as part of efforts to create insulin formulations with varying durations of action. It was introduced in the mid-20th century and became a popular choice for patients requiring insulin therapy due to its intermediate duration of action.


==Discontinuation==
== Composition ==
Lente insulin was discontinued in the United States in 2005. The decision to discontinue lente insulin was made by the manufacturer, [[Eli Lilly and Company]], due to declining demand. Since the discontinuation of lente insulin, other types of insulin with similar durations of action, such as [[NPH insulin]], have been used as replacements.
Lente insulin is a suspension of insulin zinc crystals in an acetate buffer. The formulation contains both amorphous and crystalline insulin, which contributes to its intermediate duration of action. The presence of zinc helps stabilize the insulin molecules, allowing for a slower release into the bloodstream.


==See Also==
== Mechanism of Action ==
* [[Insulin]]
Lente insulin works by facilitating the uptake of glucose into cells, particularly in the liver, muscle, and adipose tissue. This action helps lower blood glucose levels and is essential for the management of diabetes. The intermediate action of Lente insulin is due to the gradual dissolution of the insulin zinc crystals, providing a steady release of insulin over time.
 
== Administration ==
Lente insulin is typically administered via subcutaneous injection. The timing and dosage depend on the individual's needs, blood glucose monitoring, and the advice of a healthcare provider. It is often used in combination with other types of insulin to achieve optimal blood glucose control.
 
== Advantages and Disadvantages ==
=== Advantages ===
* Provides a more stable and prolonged insulin action compared to short-acting insulins.
* Can be used in combination with other insulin types for tailored diabetes management.
 
=== Disadvantages ===
* May not provide adequate control of postprandial blood glucose spikes.
* Requires careful monitoring and adjustment to avoid hypoglycemia.
 
== Related Pages ==
* [[Diabetes mellitus]]
* [[Diabetes mellitus]]
* [[Type 1 diabetes]]
* [[Insulin therapy]]
* [[Type 2 diabetes]]
* [[Insulin analogs]]
* [[NPH insulin]]
* [[Hypoglycemia]]


[[Category:Insulin]]
{{Diabetes}}
[[Category:Diabetes]]


{{stub}}
[[Category:Insulin therapies]]

Latest revision as of 16:27, 16 February 2025

Lente Insulin[edit]

3D structure of human insulin hexamer

Lente insulin is a type of intermediate-acting insulin used in the management of diabetes mellitus. It is designed to mimic the body's natural pattern of insulin release and is typically administered to help control blood glucose levels throughout the day.

History[edit]

Lente insulin was developed as part of efforts to create insulin formulations with varying durations of action. It was introduced in the mid-20th century and became a popular choice for patients requiring insulin therapy due to its intermediate duration of action.

Composition[edit]

Lente insulin is a suspension of insulin zinc crystals in an acetate buffer. The formulation contains both amorphous and crystalline insulin, which contributes to its intermediate duration of action. The presence of zinc helps stabilize the insulin molecules, allowing for a slower release into the bloodstream.

Mechanism of Action[edit]

Lente insulin works by facilitating the uptake of glucose into cells, particularly in the liver, muscle, and adipose tissue. This action helps lower blood glucose levels and is essential for the management of diabetes. The intermediate action of Lente insulin is due to the gradual dissolution of the insulin zinc crystals, providing a steady release of insulin over time.

Administration[edit]

Lente insulin is typically administered via subcutaneous injection. The timing and dosage depend on the individual's needs, blood glucose monitoring, and the advice of a healthcare provider. It is often used in combination with other types of insulin to achieve optimal blood glucose control.

Advantages and Disadvantages[edit]

Advantages[edit]

  • Provides a more stable and prolonged insulin action compared to short-acting insulins.
  • Can be used in combination with other insulin types for tailored diabetes management.

Disadvantages[edit]

  • May not provide adequate control of postprandial blood glucose spikes.
  • Requires careful monitoring and adjustment to avoid hypoglycemia.

Related Pages[edit]